ann
arvin
stanford
univers
ca
usa
present
us
latest
varicella
zoster
vaccin
develop
food
drug
administr
fda
approv
use
liveattenu
la
varicella
zoster
viru
vzv
okastrain
vaccin
vaccin
commenc
mani
countri
year
clinic
practic
clear
vaccin
effect
provid
protect
infect
wildtyp
wt
viru
efficaci
protect
seriou
diseas
breakthrough
infect
vaccin
viru
occur
vaccine
gener
mild
zoster
caus
reactiv
vzv
latenc
common
among
hematopoieticcel
transplant
recipi
vaccin
inactiv
vzv
vaccin
shown
reduc
risk
zoster
individu
correl
reconstitut
vzvspecif
tcell
immun
stanley
plotkin
address
latest
develop
vaccin
cytomegaloviru
cmv
congenit
infect
cmv
common
caus
neurolog
disord
infant
unit
state
cmv
transmit
birth
caus
death
sequala
case
prevent
death
well
cmv
infect
transplant
recipi
patient
research
start
explor
possibl
vaccin
cmv
current
four
differ
cmv
candid
vaccin
test
phase
ii
trial
la
vaccin
base
town
strain
induc
good
immun
includ
neutral
antibodi
cellmedi
immun
correl
protect
howev
immun
respons
lag
behind
natur
infect
increas
immunogen
town
la
vaccin
lack
nineteen
open
read
frame
orf
lost
capac
establish
latenc
orf
virul
toledo
strain
cmv
introduc
town
vaccin
strain
addit
two
candid
la
vaccin
subunit
candid
vaccin
compris
gb
glycoprotein
canarypox
vector
contain
iei
exon
test
phase
trial
former
induc
antibodi
wherea
latter
induc
strong
cellular
immun
respons
end
age
spectrum
elderli
gener
reduc
immun
function
innat
adapt
immun
system
socal
immunosenesc
caus
increas
morbid
mortal
age
group
reduc
immun
function
vaccin
efficaci
often
lower
elderli
vaccin
immunogen
obtain
similar
seroconvers
rate
michael
roggendorf
univers
essen
essen
germani
show
immunogen
hepat
viru
hav
hepat
b
viru
hbv
vaccin
lower
elderli
measur
seroconvers
rate
interestingli
efficaci
hav
hbv
vaccin
differ
individu
year
age
seroconvers
respect
may
depend
natur
vaccin
formul
llui
sallera
autonom
govern
catalonia
barcelona
spain
elabor
vaccin
efficaci
demonstr
hav
hbv
vaccin
preadolesc
schoolchildren
effect
protect
diseas
respiratori
syncyti
viru
rsv
singlestrand
neg
sens
rna
viru
belong
famili
paramyxovirida
genu
pneumoviru
upon
infect
viru
caus
upper
respiratori
tract
diseas
age
group
howev
sever
complic
often
seen
young
elderli
bone
marrow
transplant
patient
late
vaccin
experi
conduct
young
children
use
formalininactiv
rsv
firsv
upon
infect
wt
strain
rsv
children
suffer
sever
complic
result
death
phenomenon
enhanc
diseas
firsv
vaccin
children
hamper
rsv
vaccin
research
enorm
understand
mechan
diseas
enhanc
key
issu
crucial
rsv
vaccin
develop
peter
openshaw
cowork
studi
enhanc
diseas
mice
mani
year
possibl
involv
cell
human
bronchiol
recent
highlight
deplet
unconvent
cell
prevent
enhanc
diseas
rsvinfect
mice
previous
sensit
scarif
vaccinia
virus
encod
singl
rsv
protein
among
target
popul
vaccin
young
children
year
age
presenc
matern
antibodi
immatur
immun
system
may
reduc
immunogen
vaccin
children
jame
crow
investig
abil
b
cell
young
children
produc
neutral
antibodi
import
protect
immun
follow
natur
infect
immunoglobulin
ig
region
b
cell
produc
rsvspecif
antibodi
sequenc
gene
rearrang
result
complet
vdj
region
immunoglobulin
occur
rsvspecif
b
cell
howev
b
cell
infant
less
month
old
exhibit
strike
pauciti
somat
mutat
vh
gene
indic
unabl
produc
high
qualiti
neutral
antibodi
potenti
vaccin
candid
rsv
includ
adenoviru
recombin
immun
stimul
complex
iscom
prepar
subunit
vaccin
well
la
viru
vaccin
la
viru
vaccin
known
induc
humor
cellular
immun
respons
present
miranda
de
graaf
erasmu
mc
rotterdam
netherland
demonstr
possibl
revers
genet
creat
la
virus
work
done
use
human
metapneumoviru
hmpv
viru
caus
similar
diseas
rsv
exchang
polymeras
gene
two
differ
lineag
hmpv
attenu
abil
induc
chloramphenicol
acetyl
transferas
cat
activ
minigenom
contain
cat
report
gene
flank
hmpv
genom
end
use
fulllength
hmpv
genom
instead
report
gene
result
rescu
recombin
viabl
virus
system
could
produc
attenu
virus
may
use
vaccin
purpos
passiv
transfer
neutral
antibodi
avail
treatment
rsv
rel
short
halflif
antibodi
essenti
administr
antibodi
coincid
rsv
epidem
season
onset
vari
yeartoyear
pidari
network
pediatr
infecti
diseas
network
acut
respiratori
tract
infect
current
identifi
differ
viral
bacteri
pathogen
use
multiplex
pcr
children
year
old
josef
weigl
christian
albrecht
univers
kiel
germani
show
last
year
start
rsv
epidem
week
prior
onset
antibodi
administr
unnecessarili
endang
children
infect
rsv
data
support
need
synchron
applic
prevent
antibodi
treatment
rsv
epidem
final
rob
moormann
anim
scienc
group
wageningen
lelystad
netherland
present
latest
bovin
rsv
vaccin
develop
vaccin
firsv
induc
enhanc
diseas
anim
includ
eosinophil
influx
ige
respons
second
import
respiratori
pathogen
influenza
viru
segment
neg
sens
singlestrand
rna
viru
respons
three
major
pandem
centuri
well
annual
epidem
contrast
rsv
correl
protect
well
document
includ
presenc
neutral
antibodi
probabl
tcell
respons
influenza
vaccin
research
focus
two
area
develop
influenza
vaccin
pandem
situat
develop
altern
influenza
vaccin
prevent
diseas
follow
infect
epidem
virus
annual
classic
influenza
vaccin
trival
inactiv
influenza
vaccin
administ
year
inject
harri
greenberg
stanford
univers
school
medicin
ca
usa
gave
overview
develop
coldadapt
ca
influenza
vaccin
flumist
tm
approv
fda
use
individu
year
age
ca
virus
capabl
grow
low
temperatur
c
attenu
bodi
temperatur
genet
basi
attenu
influenza
viru
aann
identifi
limit
aminoacid
aa
chang
polymeras
protein
aa
aa
well
aa
chang
nucleoprotein
np
flumist
tm
appli
intranas
shown
effect
low
transmiss
rate
highli
suscept
young
children
day
care
set
futur
medic
import
possibl
associ
asthma
use
flumist
tm
young
children
need
investig
final
addit
data
confirm
extend
appar
safeti
efficaci
flumist
tm
individu
year
age
obtain
product
influenza
vaccin
embryon
chicken
egg
gener
master
reassort
vaccin
strain
time
consum
inflex
procedur
hamper
rapid
develop
pandem
influenza
vaccin
advent
vero
madindarbi
canin
kidney
mdck
cell
line
regist
vaccin
product
facilit
flexibl
vaccin
product
futur
compani
like
baxter
vaccin
ag
solvay
pharmaceut
bv
revers
genet
altern
tool
gener
reassort
vaccin
strain
john
wood
nation
institut
biolog
standard
control
london
uk
elabor
possibl
new
approach
point
licens
issu
dealt
order
make
quick
licens
candid
vaccin
possibl
event
futur
pandem
threat
catherin
ammon
mph
geneva
switzerland
discuss
poor
public
awar
danger
influenza
amongst
swiss
elderli
although
elderli
realiz
belong
highrisk
group
bad
experi
doubt
efficaci
side
effect
reduc
number
individu
will
take
vaccin
ensur
effect
use
influenza
vaccin
imper
public
awar
increas
maintain
high
level
dengu
viru
seriou
health
threat
human
popul
infect
million
individu
year
worldwid
robert
putnak
walter
reed
armi
institut
research
md
usa
present
overview
dengu
viru
vaccin
candid
current
test
preclin
clinic
trial
one
major
issu
concern
dengu
viru
infect
occurr
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
small
percentag
infect
individu
dhf
dss
occur
primari
infect
occur
much
frequent
secondari
dengu
viru
infect
serotyp
differ
primari
infect
suggest
antibodi
mediat
enhanc
wane
immun
may
play
role
pathogenesi
complic
earli
dengu
viru
candid
vaccin
consist
la
viru
strain
develop
dr
sabin
vaccin
studi
demonstr
la
candid
vaccin
partial
protect
challeng
live
viru
safe
well
toler
immunogen
sinc
resolut
dengu
viru
four
differ
candid
vaccin
current
evalu
preclin
clinic
trial
includ
two
candid
la
viru
vaccin
two
recombin
candid
vaccin
monoval
la
vaccin
candid
vari
immunogen
four
serotyp
dengu
viru
interf
multipl
dose
vaccin
given
month
apart
requir
obtain
satisfi
seroconvers
rate
recombin
dengu
viru
serotyp
develop
nation
institut
health
also
promis
candid
induc
seroconvers
rate
human
volunt
recombin
yellowfev
yf
viru
contain
prm
envelop
e
protein
dengu
viru
chimerivax
tm
konstantin
pugachev
acambi
inc
usa
prove
potenti
singl
dose
four
serotyp
provid
protect
challeng
infect
day
later
cynomolguo
macaqu
also
candid
subunit
vaccin
develop
dengu
viru
carolyn
weekslevi
hawaii
biotech
inc
hi
usa
present
data
subunit
candid
vaccin
consist
recombin
envelop
protein
e
lack
transmembran
region
interestingli
monkey
vaccin
high
dose
monoval
serotyp
dengu
viru
e
protein
becam
virem
upon
infect
lower
vaccin
dosag
result
viremia
addit
nonstructur
ns
protein
increas
cellular
immun
respons
improv
protect
immun
wellington
sun
walter
reed
armi
institut
research
md
usa
compar
candid
dengu
viru
vaccin
efficaci
observ
human
monkey
monkey
permiss
infect
dengu
viru
show
diseas
symptom
includ
dhf
dss
upon
infect
anim
clear
viru
develop
antibodi
partial
crossprotect
present
unclear
whether
monkey
model
valid
predict
outcom
vaccin
human
seroconvers
rate
monoand
tetraval
candid
vaccin
gener
lower
human
monkey
chimerivax
tm
recombin
yf
viru
contain
prm
envelop
e
protein
dengu
viru
serotyp
candid
vaccin
elicit
seroconvers
rate
human
walter
reed
group
conduct
serotyp
dengu
serotyp
dengu
viru
challeng
studi
subject
vaccin
tetraval
la
candid
vaccin
result
indic
rhesu
monkey
viremia
correl
well
result
human
although
human
challeng
model
import
valid
vaccin
efficaci
role
vaccin
develop
remain
defin
regina
kofler
univers
vienna
vienna
austria
describ
isol
attenu
tickborn
enceph
viru
tbev
delet
capsid
protein
secondsit
mutat
restor
capac
attenu
viru
replic
cellcultur
mutant
shown
potenti
develop
live
flaviviru
vaccin
yf
viru
strain
attenu
viru
strain
lost
viscerotrop
neurotrop
vector
compet
phenotyp
wildtyp
yf
viru
use
backbon
vaccin
induct
immun
flavivirus
therefor
full
understand
molecular
determin
attenu
virul
import
alan
barrett
univers
texa
medic
branch
galveston
usa
show
none
aa
substitut
could
link
neuroand
hepatotrop
howev
e
protein
may
import
determin
viru
phenotyp
second
member
flavivirida
famili
high
impact
human
health
hepat
c
viru
hcv
origin
identifi
believ
infect
million
peopl
worldwid
approxim
hcv
acut
infect
resolv
spontan
appear
associ
strong
thelper
cell
antibodi
respons
current
main
aim
vaccin
prevent
occurr
chronic
liver
diseas
infect
hcv
sinc
chimpanze
speci
human
suscept
infect
use
evalu
efficaci
hcv
candid
vaccin
michael
houghton
chiron
corpor
ca
usa
demonstr
vaccin
adjuv
recombin
glycoprotein
gp
subsequ
challeng
hcv
rna
significantli
reduc
incid
chronic
diseas
chimpanze
studi
steril
immun
associ
high
level
neutral
antibodi
neutral
antibodi
may
prevent
bind
hcv
particl
demonstr
vitro
hyperimmun
serum
infect
individu
current
subunit
candid
vaccin
test
phase
trial
west
nile
viru
wnv
introduc
usa
prompt
extra
effort
develop
vaccin
wnv
transmit
bird
human
mosquito
caus
febril
ill
approxim
infect
individu
infect
individu
infect
result
neurolog
disord
follow
death
case
michael
lieberman
hawaii
biotech
inc
hi
usa
show
vaccin
truncat
e
protein
wnv
protect
golden
hamster
infect
wnv
evalu
candid
subunit
vaccin
acambi
chimer
fort
dodg
kill
candid
vaccin
need
demonstr
safeti
efficaci
human
lorn
babiuk
univers
saskatoon
sask
canada
introduc
field
veterinari
vaccinolog
veterinari
vaccin
also
safe
efficaci
perhap
contrast
vaccin
human
use
gener
cheap
fit
exist
practic
furthermor
veterinari
vaccin
often
evalu
directli
target
speci
addit
convent
live
inactiv
vaccin
also
genet
engin
chimer
dna
plantbas
replic
defect
veterinari
vaccin
avail
vaccin
aim
induct
protect
immun
human
pathogen
order
prevent
contamin
food
water
agent
also
includ
bacteria
escherichia
coli
e
coli
strain
campylobact
salmonella
alvac
vector
canarypox
vector
one
vector
use
veterinari
vaccin
among
mani
advantag
inabl
replic
mammalian
cell
larg
code
capac
induct
low
level
vector
immun
abil
overcom
matern
antibodi
huw
hugh
merial
lyon
franc
demonstr
regist
alvac
vector
express
hemagglutinin
ha
influenza
viru
protect
hors
infect
addit
antibodi
titer
remain
high
least
year
follow
second
vaccin
also
coronaviru
vector
develop
demonstr
lui
enjuan
centro
nacion
de
csic
madrid
spain
singlestrand
posit
sens
rna
viru
dna
intermedi
minim
risk
chromosom
integr
vector
addit
variat
spike
protein
control
tropism
viru
target
certain
area
bodi
final
reinfect
coronavirus
occur
frequent
suggest
preexist
immun
easili
overcom
viru
construct
bacteri
artifici
chromosom
contain
fulllength
transmiss
gastroenter
viru
tgev
allow
genet
manipul
viru
shown
eprotein
defici
tgev
viru
replic
packag
celllin
express
eprotein
reloc
packag
signal
e
gene
like
recombin
site
eprotein
defici
virus
becom
propag
compet
lead
product
highli
safe
coronaviru
vector
certain
attenu
virus
use
vector
antigen
deliveri
foreign
viral
antigen
attenu
may
achiev
reduc
replic
capac
eg
yf
strain
modifi
vaccinia
ankara
mva
base
speci
restrict
eg
canarypox
vector
alvac
vector
induc
strong
humor
cellular
immun
respons
specif
protein
interest
gerd
sutter
gsfinstitut
molecular
virolog
muenchen
germani
elabor
progress
made
regard
develop
mva
vector
technolog
mva
use
condit
biosafeti
level
avirul
defici
product
grow
human
cell
anim
model
mva
vaccin
found
immunogen
protect
variou
infecti
agent
includ
immunodefici
virus
data
clinic
trial
present
provid
evid
safeti
immunogen
recombin
mva
use
therapeut
vaccin
hivinfect
individu
final
shown
modif
immun
regulatori
gene
interferon
resist
gene
interleukininhibitor
sequenc
conserv
within
mva
genom
might
provid
basi
develop
advanc
second
gener
mva
vaccin
even
higher
immunogen
anoth
viral
vector
semlikiforest
viru
sfv
featur
dna
rna
viral
vector
induct
immun
respons
foreign
antigen
sfv
replicon
produc
foreign
protein
use
vaccin
also
nake
rna
cdna
replicon
use
vaccin
foreign
antigen
peter
karolinska
institut
stockholm
sweden
report
replicas
protein
sfv
play
import
role
matur
dendrit
cell
dc
also
shown
sfv
capabl
induc
crossprim
matur
dc
well
interferon
ifn
product
provid
enough
danger
signal
induc
vigor
immun
respons
foreign
antigen
explain
good
immunogen
potenti
modul
hcvspecif
immun
respons
use
cytokin
test
christin
rollier
biomed
primat
research
center
rijswijk
netherland
addit
dna
plasmid
encod
interleukin
il
enhanc
immunogen
candid
dna
vaccin
base
protein
hcv
rhesu
macaqu
melero
use
state
art
technolog
identifi
fusion
properti
fusion
site
rsv
fusion
protein
fprotein
futur
research
aim
develop
compound
antibodi
capabl
bind
fusogen
intermedi
fprotein
ideal
vaccin
combin
low
reactogen
high
immunogen
profil
order
safe
efficaci
unfortun
characterist
often
go
hand
hand
result
immunogen
reactogen
vaccin
therefor
research
tri
enhanc
immunogen
vaccin
primeboost
regimen
use
adjuv
altern
method
vaccin
guu
rimmelzwaan
erasmu
mc
rotterdam
netherland
summar
find
three
differ
studi
conduct
three
differ
speci
use
iscom
contain
ha
neuraminidas
na
variou
influenza
virus
monkey
chicken
protect
infect
subtyp
highli
pathogen
subtyp
influenza
viru
respect
vaccin
iscom
base
vaccin
convent
subunit
vaccin
protect
correl
vigor
antibodi
tcell
respons
human
preexist
immun
influenza
viru
ad
valu
adjuv
less
pronounc
howev
kinet
virusspecif
antibodi
respons
acceler
iscom
vaccin
individu
compar
receiv
convent
vaccin
addit
iscom
vaccin
induc
ctl
respons
wherea
classic
vaccin
vaccin
often
administ
intramuscularli
im
altern
administr
method
may
enhanc
immunogen
certain
vaccin
lendon
payn
powderject
vaccin
inc
wi
usa
demonstr
powderject
tm
deliv
dna
protein
epidermi
known
contain
uniqu
popul
langerhan
cell
epiderm
powder
immun
also
combin
certain
adjuv
like
e
coli
heatlabil
enterotoxin
lt
dna
subunit
vaccin
coadministr
lt
induc
strong
cellular
immun
respons
mice
jan
wilschut
univers
groningen
groningen
netherland
present
data
use
virosom
possibl
carrier
influenza
viral
glycoprotein
virosom
reconstitut
viral
envelop
without
viral
genom
shown
induc
humor
cellular
immun
mice
addit
virosom
capabl
harbor
aliphat
adjuv
enhanc
potenti
induc
immun
viral
glycoprotein
final
annek
boonstra
covaccin
bv
lelystad
netherland
inform
us
latest
develop
dissacharid
fatti
acid
sulphat
ester
adjuv
experi
demonstr
one
sulphat
combin
seven
lauric
acid
squalaneinwat
induc
high
level
influenza
virusspecif
antibodi
pig
human
gari
nabel
nation
institut
health
bethesda
usa
present
recent
data
human
immunodefici
viru
hiv
candid
vaccin
test
monkey
inclus
envelop
gene
candid
vaccin
plasmid
dnarecombin
adenoviru
primeboost
regiment
enhanc
humor
cellular
immun
respons
correl
immun
protect
use
high
dose
plasmid
dna
milligram
hivspecif
tcell
respons
induc
high
percentag
individu
one
mysteri
hiv
transmiss
virus
virus
upon
infect
new
data
demonstr
virus
infect
immatur
dc
wherea
virus
immatur
dc
upon
matur
mediat
viral
transfer
cell
sinc
whole
process
done
within
cell
highli
resist
neutral
antibodi
activ
mechan
may
contribut
preferenti
transmiss
virus
may
implic
futur
vaccin
design
dnaprim
adenoviru
vector
boost
vaccin
regiment
current
seem
best
method
induc
high
tcell
respons
preexist
antibodi
adenoviru
howev
interfer
efficaci
vaccin
jaap
goudsmit
crucel
nv
leiden
netherland
identifi
altern
adenoviru
serotyp
low
seropreval
human
popul
adenoviru
serotyp
shown
low
global
seropreval
low
infect
rate
hiv
posit
neg
individu
make
viru
attract
viral
vector
duncan
steel
geneva
switzerland
offer
us
latest
rotaviru
vaccin
develop
rotaviru
import
pathogen
young
children
claim
half
million
death
year
particular
develop
countri
rotaviru
complex
tripl
layer
viru
two
neutral
antigen
involv
immun
respons
host
vaccin
strategi
differ
need
develop
homoand
heterotyp
immun
specif
antigen
current
two
la
rotaviru
vaccin
licens
rotashield
wyeth
vaccin
tetraval
rhesu
rotaviru
vaccin
demonstr
protect
rotaviru
diarrhea
sever
diseas
howev
vaccine
develop
fever
upon
vaccin
elev
risk
develop
intussuscept
vaccine
reason
rotashield
vaccin
withdrawn
second
la
rotaviru
vaccin
manufactur
china
although
efficaci
truli
children
remain
demonstr
two
candid
rotaviru
vaccin
late
stage
develop
rotateq
merck
research
rotarix
gsk
biolog
efficaci
candid
vaccin
similar
earli
clinic
trial
approxim
effect
prevent
rotaviru
diarrhea
rotashield
futur
reveal
two
candid
vaccin
ie
two
dose
rotarix
three
dose
oral
vaccin
rotateq
provid
better
heterolog
longterm
protect
prior
clinic
use
rotaviru
candid
vaccin
potenti
interfer
live
oral
polioviru
vaccin
safeti
immunogen
efficaci
hivinfect
children
investig
threat
emerg
viral
infect
terrorist
attack
biolog
weapon
trigger
major
effort
find
cure
vaccin
agent
jame
leduc
point
issu
involv
candid
vaccin
emerg
rare
diseas
difficulti
rare
viral
diseas
inabl
demonstr
efficaci
human
fda
approv
therefor
base
data
obtain
monkey
whose
predict
valu
regard
efficaci
safeti
remain
controversi
issu
involv
fast
track
vaccin
regulatori
author
cover
intern
properti
right
liabil
issu
differ
viewpoint
govern
industri
includ
willing
justifi
develop
certain
vaccin
gari
nabel
present
data
ebola
viru
vaccin
develop
glycoprotein
gp
ebola
viru
caus
cell
round
detach
human
endotheli
epitheli
cell
effect
requir
presenc
mucinlik
domain
gp
correspond
downregul
cell
surfac
gp
import
vaccin
candid
howev
passiv
transfer
antibodi
human
monkey
confer
protect
infect
vaccin
experi
therefor
aim
induct
humor
cellular
immun
respons
ebola
viru
surprisingli
monkey
vaccin
adenovir
vector
encod
gp
np
ebola
viru
protect
high
dose
challeng
us
govern
decid
everi
citizen
abl
receiv
smallpox
vaccin
origin
dryvax
vaccin
consist
heterogen
virion
subpopul
may
contamin
rumin
virus
richard
weltzin
acambi
inc
usa
present
data
plaqu
purif
origin
viru
stock
yield
isol
prove
immunogen
without
neurovirul
mice
monkey
current
viru
test
phase
ii
trial
smallpox
vaccin
scarif
vaccinia
viru
crude
method
quantit
requir
skill
personnel
also
result
activ
local
lesion
shed
live
viru
method
vaccin
may
quantit
shed
live
viru
amanda
phelp
biomed
scienc
porton
uk
show
intramuscular
vaccin
mice
provid
better
protect
lower
vaccin
dose
needlefre
microject
scarif
method
sever
acut
respiratori
syndrom
sar
import
emerg
infecti
diseas
caus
sarscov
current
cure
vaccin
exist
mice
shown
dna
encod
spike
protein
sarscov
induc
spike
proteinspecif
antibodi
antibodi
antiserum
recov
patient
shown
gari
nabel
inhibit
gene
transfer
pseudotyp
viru
contain
spike
protein
sarscov
addit
kiril
kalnin
acambi
inc
usa
demonstr
hyper
immun
serum
sarscov
infect
individu
react
recombin
spike
protein
data
suggest
spike
protein
sarscov
may
good
vaccin
candid
viral
vaccin
meet
end
seri
present
emerg
sarscov
februari
report
first
case
sarscov
march
new
coronaviru
sarscov
identifi
three
laboratori
two
week
later
entir
genom
viru
sequenc
close
follow
fulfil
koch
postul
import
hallmark
sarscov
identif
viru
sever
anim
speci
includ
palm
civet
albert
osterhau
show
abil
sarscov
infect
macaqu
differ
carnivor
speci
includ
housecat
ferret
end
epidem
sever
import
conclus
could
drawn
among
risk
factor
advers
outcom
diseas
age
year
diabet
heart
diseas
comorbid
condit
earli
epidem
note
healthcar
worker
risk
contract
diseas
may
due
rel
late
peak
virustit
day
onset
ill
subject
health
care
worker
high
dose
viru
rel
late
peak
viru
titer
also
hamper
diagnosi
sarscov
malik
peiri
queen
mari
hospit
hong
kong
sar
show
improv
rna
extract
realtim
pcr
increas
percentag
posit
swab
consider
posit
day
day
prepar
second
introduct
sarscov
human
popul
antivir
drug
protect
vaccin
urgent
need
lui
enjuan
first
clone
fulllength
genom
coronaviru
tgev
delet
e
protein
reloc
packag
signal
gener
safe
efficaci
vaccin
candid
fulllength
sarscov
genom
clone
may
augment
gener
candid
sarscov
vaccin
meet
end
present
jan
hendrik
public
health
director
european
commiss
luxembourg
behalf
european
commiss
highlight
opportun
stumbl
block
develop
viral
vaccin
major
import
public
health
meet
provid
overview
viral
vaccin
current
use
human
anim
vari
degre
success
also
gave
state
art
view
novel
develop
opportun
field
